Predicting surgical outcomes in single-port robot-assisted partial nephrectomy: external validation and comparative analysis of PADUA, RENAL, and SPARE scores - Scorecard - MDSpire

Predicting surgical outcomes in single-port robot-assisted partial nephrectomy: external validation and comparative analysis of PADUA, RENAL, and SPARE scores

  • By

  • Filippo Carletti

  • Fabio Maria Valenzi

  • Flavia Tamborino

  • Alexandru Turcan

  • Valerio Santarelli

  • Arianna Biasatti

  • Luca Alfredo Morgantini

  • Hakan Bahadir Haberal

  • Srinivas Vourganti

  • Fabrizio Dal Moro

  • Riccardo Autorino

  • Simone Crivellaro

  • November 20, 2025

  • 0 min

Share

Clinical Scorecard: Evaluating Surgical Outcomes in Single-Port Robot-Assisted Partial Nephrectomy: External Validation and Comparative Study of PADUA, RENAL, and SPARE Scoring Systems

At a Glance

CategoryDetail
ConditionT1 renal tumors undergoing single-port robot-assisted partial nephrectomy (SP-RAPN)
Key MechanismsUse of anatomical nephrometry scores (PADUA, RENAL, SPARE) to predict surgical outcomes including Trifecta achievement
Target PopulationPatients with solitary ≤ cT2 renal tumors without lymph-node or distant metastases
Care SettingSurgical treatment in academic institutions using da Vinci SP robotic platform

Key Highlights

  • SP-RAPN with retroperitoneal approach provides direct renal hilum access without bowel mobilization
  • PADUA, RENAL, and SPARE nephrometry scores quantify tumor complexity and predict perioperative outcomes
  • Trifecta achievement (negative margins, no complications, WIT ≤ 25 min) used as primary surgical outcome measure

Guideline-Based Recommendations

Diagnosis

  • Preoperative CT or MRI within 90 days prior to surgery for tumor assessment
  • Use of standardized nephrometry scores (PADUA, RENAL, SPARE) for anatomical tumor evaluation

Management

  • Perform SP-RAPN via retroperitoneal or transperitoneal approach using da Vinci SP system
  • Surgical planning guided by nephrometry scores to anticipate complexity and morbidity
  • Surgeon discretion on enucleoresection versus tumor enucleation techniques

Monitoring & Follow-up

  • Record intraoperative variables including WIT, estimated blood loss, operative time, and use of vascular clamping
  • Monitor perioperative complications graded by Clavien–Dindo classification within 90 days post-surgery
  • Assess renal function changes pre- and post-operatively via estimated glomerular filtration rate

Risks

  • Consider patient comorbidities such as hypertension, diabetes, and ASA score in surgical risk assessment
  • Recognize moderate interobserver variability in nephrometry scoring; use consensus for ambiguous cases
  • Exclude patients with solitary kidney, end-stage renal disease, or recurrent renal cell carcinoma from SP-RAPN

Patient & Prescribing Data

211 patients with solitary ≤ cT2 renal tumors undergoing SP-RAPN

Majority male, median age 60, with common comorbidities including hypertension and diabetes; most tumors intermediate complexity by PADUA and low complexity by RENAL and SPARE scores

Clinical Best Practices

  • Use nephrometry scores to standardize tumor complexity assessment and guide surgical planning
  • Employ retroperitoneal approach preferentially in SP-RAPN for direct renal hilum access
  • Achieve Trifecta outcomes by ensuring negative margins, minimizing complications, and limiting warm ischemia time to ≤ 25 minutes

References

Original Source(s)

Related Content